News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Kalkine Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
An investor group comprising 3i, LP, Tumim Stone Capital, LLC, 3i Management LLC, and Maier J. Tarlow has filed an amended Schedule 13D for Valion Bio, Inc. (VBIO), reporting beneficial ownership of 1,742,699 common shares, representing a 9.9% stake. This percentage is calculated based …
Valion Bio, Inc. (OTC: VBIO) has reported significant financial concerns, including a net loss of $13.3 million for the first six months of 2026 and an accumulated deficit of $66.5 million, raising substantial doubt about its ability to continue as a going concern. The …
Lionheart Holdings (NASDAQ: CUB), a SPAC, filed its Q2 2026 SEC Form 10-Q on August 14, 2026, detailing its status as a shell company and outlining its capital structure. The company has a deadline of March 20, 2027, to complete an initial business combination, …
Valion Bio, Inc. reported a significant widening of its net loss in Q2 2026 to $7.1M, up from $1.93M in Q2 2025, with diluted loss per share at $(2.17). The company recorded no revenue from continuing operations. Despite financial losses, Valion Bio highlighted progress …
Lionheart Holdings (CUB), a Cayman Islands SPAC, reported a net loss of $2.7 million for the six months ended June 30, 2026, driven by high general and administrative expenses including a $6.5 million non-redemption agreements expense. The company extended its business combination deadline to …
First Trust entities have filed an amended passive investment disclosure (SCHEDULE 13G/A) revealing their minority stakes in Lionheart Holdings. First Trust Merger Arbitrage Fund (VARBX) holds 3.34% of Class A Ordinary Shares, while First Trust Capital Management L.P., First Trust Capital Solutions L.P., and …
Harraden Circle Investments, LLC and Frederick V. Fortmiller, Jr. have reported a beneficial ownership of 1,297,683 Class A shares, representing 5.64% of Lionheart Holdings (CUB), through an amended Schedule 13G filing. This amendment reflects an internal reorganization effective June 30, 2026, and updates the …
LMR-affiliated investment managers Ben Levine and Stefan Renold, through funds they manage, have reported a 3.5% passive equity stake in Lionheart Holdings (CUB). As of June 30, 2026, these funds collectively held 750,000 Class A ordinary shares. Additionally, the LMR funds also hold warrants …
Medallion Financial (MFIN) shares have surpassed their 200-day moving average, trading at $11.43 against an average of $9.72. Despite this, analysts maintain a "Hold" rating with a $10.50 target price, which is below the current trading level. The company recently exceeded earnings and revenue …
Decagon Asset Management LLP and Benjamin John Durham have reported a beneficial ownership of 1,500,000 Class A ordinary shares in Lionheart Holdings (NYSE: CUB), which constitutes a 6.52% stake in the company. Both parties maintain sole voting and dispositive power over these shares, with …
AQR Capital Management, LLC, along with AQR Capital Management Holdings, LLC and AQR Arbitrage, LLC, has disclosed an amended beneficial ownership of 1,400,000 Class A ordinary shares in Lionheart Holdings (CUB), representing 6.51% of the outstanding class. The entities hold shared voting and dispositive …
This article provides an analysis of Valion Bio (Nasdaq: VBIO), an advanced-stage biopharmaceutical company with a market capitalization of US$546.7k. The company is developing Entolimod for Acute Radiation Syndrome (ARS) and oncology supportive care, facing significant risks including a highly volatile stock price, declining …
Valion Bio (Nasdaq: VBIO) announced that Ukraine's Ministry of Health has accepted the regulatory dossier for its ARS countermeasure, Entolimod, for formal review. A favorable decision, which could come as early as Q4 2026, would mark Entolimod's first national registration and could lead to …
This article reports on Valion Bio, Inc.'s SEC Filing of type EFFECT on August 13, 2026. The filing has a neutral impact and sentiment, indicating that it is a routine notice of effectiveness for an S-1 registration form. The filing concerns Valion Bio, Inc. …
Lionsgate Studios Corp. (NYSE:LION) has received a "Moderate Buy" consensus recommendation from analysts, with an average 12-month price target of $15.575, exceeding its current share price of $11.73. Recent analyst actions include downgrades to "neutral" by Citigroup and Zacks Research, while Barrington Research and …
BillionToOne, Inc.'s Senior Vice President of Laboratory Operations, John Roderick ten Bosch, sold 1,417 shares of Class A Common Stock on August 10, 2026, at $92.86 per share, totaling approximately $132,000. This transaction was conducted under a Rule 10b5-1 trading plan established on March …
This article provides a company profile for Valion Bio Inc. (VBIO), detailing its operations as a bio-electronic health-tech company developing micro current therapy solutions. It includes key financial facts such as market capitalization, 52-week high and low prices, current and previous day's stock prices, …
Lionheart Holdings Class A Ordinary Shares (NASDAQ:CUB) experienced a significant surge in short interest in July, increasing by 610.8% to 18,268 shares, although this represents only about 0.1% of its total shares. Analyst sentiment for CUB remains negative, with a consensus "Sell" rating, despite …
Valion Bio Inc. (NASDAQ:VBIO) is commencing a safety study for its drug Entolimod, aimed at treating radiation-induced gastrointestinal injury. The study, funded by a government program, will confirm the drug's tolerability in animals, with a therapeutic study to follow and top-line data expected in …
Search by ticker symbol or company name and select a result to open its chart.